Exane Intégrale: a “daily-liquidity” UCITS fund frozen for five years

Green BNP Paribas hourglass labelled « 5 ans d'attente », symbolising five years of frozen fund liquidity

Written by

in

Investigation · Markets · Investor protection

Marketed as a safe investment under Europe’s UCITS directive, the Luxembourg fund Exane Intégrale was suspended in March 2020 and placed into liquidation. Five years on, its investors have not been repaid. A criminal complaint has been filed, and the Paris Court of Appeal has validated a seizure of documents. The facts, on the record.

Green BNP Paribas hourglass labelled « 5 ans d'attente », symbolising five years of frozen fund liquidity
The net asset value of the Exane Intégrale fund has been suspended since 23 March 2020. Since then, investors can neither exit nor be repaid. Illustration.

On paper, it was one of the most tightly regulated products available: a fund compliant with Europe’s UCITS directive, offering daily liquidity — the promise of getting your money back on any business day. The Exane Intégrale fund, managed by Exane Asset Management with BNP Paribas Securities Services as custodian, was aimed at professional and institutional investors known for their caution.

On 23 March 2020, at the height of the Covid-19 market turmoil, that promise collapsed: the net asset value was suspended, and the fund was placed into liquidation. Five years later, according to the public documents available, that liquidation is still not complete and holders have not been paid out.

A fund sold as “liquid every day” is, five years on, still closed — and savers are still waiting for their money.

What the documents say

According to a shareholder notice from Exane Funds 1 dated 1 April 2020, followed by a liquidation progress report dated 8 November 2020, the management company confirmed the freeze of the sub-fund. The specialist press documented the episode from the outset: Les Échos reported, on 25 March 2020, that “the French manager Exane AM” had frozen one of its funds.

According to Exane AM, as quoted in the press, several over-the-counter (OTC) derivatives held in the portfolio saw their valuation diverge “significantly from their theoretical value” during the March 2020 crisis. It is around this point — and the early termination of certain derivative contracts by counterparties — that today’s questions crystallise.

An open judicial chapter

The affair has turned litigious. As reported by L’Agefi and Les Échos on 17 October 2022, and by Citywire, an institutional investor trapped in the fund filed a complaint against unknown parties (“contre X”) before the Paris judicial court. According to those same sources, the complaint cites the criminal characterisations of breach of trust, forgery and use of forgery, dissemination of false or misleading information and fraudulent introduction of data into an automated processing system.

The complainant is also said to question the early termination of OTC derivative contracts by certain counterparties in March 2020 and possible conflicts of interest among entities of the BNP Paribas group.

To be precise: a complaint against unknown parties is neither a charge nor a conviction. It opens an investigation. At this stage, no court has established criminal liability against anyone, and the entities named benefit from the presumption of innocence.

The Court of Appeal validates a seizure of documents

Procedurally, a step was taken in 2025. According to L’Agefi (3 April 2025), the Paris Court of Appeal validated the seizure of documents carried out at Exane AM, following a ruling of its Pôle 1 – Chamber 8 (docket 24/06346, judgment of 21 March 2025). In practice, this decision allows documents to be preserved and used as part of the investigation — a foothold for the inquiry, without prejudging its outcome.

The auditors’ qualified opinion

Exane Funds’ annual reports offer further light. According to the audit reports signed by PwC, a qualified opinion was issued regarding the Exane Intégrale sub-fund (2022 financial year), and the 2024 annual report notes, on page 22, that the liquidation is “still ongoing.” A qualified opinion signals that the auditor could not obtain all the evidence needed to give an unqualified opinion on the accounts — a warning sign for any investor.

Why this matters for savers

Beyond the specific case, the Exane Intégrale affair raises a fundamental question: what is the “daily liquidity” promise of a UCITS fund actually worth when a crisis hits? The UCITS label is often presented as a guarantee of safety and ease of exit. This episode shows that a regulated fund can, in practice, stay closed for years, locking up its holders’ savings.

For investors — institutional and retail alike — three reflexes stand out: read the audit reports (and spot any qualified opinion), understand the share of OTC derivatives and the role of counterparties in a supposedly “liquid” fund, and follow shareholder notices in the event of a suspension.

Official sources and references

  • 25/03/2020 — Les Échos, “Coronavirus: French manager Exane AM freezes one of its funds.” Document
  • 01/04/2020 — Exane Funds 1, shareholder notice on Exane Intégrale. Document
  • 08/11/2020 — Exane Funds 1, liquidation progress report. Document
  • 17/10/2022 — L’Agefi, “Exane AM’s troubles take a judicial turn.” Document
  • 17/10/2022 — Les Échos, complaint for breach of trust and forgery. Document
  • 2022 — Exane Funds annual report (PwC), qualified opinion on Exane Intégrale. Document
  • 2024 — Exane Funds annual report (PwC), liquidation still ongoing (p. 22). Document
  • 21/03/2025 — Paris Court of Appeal, Pôle 1 – Chamber 8, docket 24/06346. Judgment
  • 03/04/2025 — L’Agefi, “Exane Intégrale fund: the Court of Appeal validates the seizure of documents at Exane AM.” Document
  • Official liquidation publication — Swiss Fund Data (ref. a13-15200). Document
  • Le Temps, “The intriguing implosion of a Luxembourg fund.” Article

Frequently asked questions

What is the Exane Intégrale fund?

A Luxembourg investment fund compliant with the UCITS directive, offering daily liquidity, managed by Exane Asset Management, with BNP Paribas Securities Services as custodian.

Why is the fund frozen?

Its net asset value was suspended on 23 March 2020, at the height of the Covid-19 crisis, and the fund was placed into liquidation. According to Exane AM, OTC derivatives had diverged sharply from their theoretical value.

Have investors been repaid?

According to the available annual reports, the liquidation was still ongoing in 2024 and holders had not been paid out five years after the suspension.

Where does the legal case stand?

An institutional investor filed a complaint against unknown parties in Paris. In 2025, the Paris Court of Appeal validated a seizure of documents at Exane AM. No criminal liability has been established at this stage and the presumption of innocence applies.

Disclaimer. This article reports facts documented by public sources (shareholder notices, audit reports, court decisions, financial press). The criminal characterisations mentioned stem from a complaint and in no way prejudge the guilt of the persons or entities named, who benefit from the presumption of innocence. This article is not investment advice. Any concerned party with additional information or a right of reply may contact us.